Literature DB >> 12082547

Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector.

Jeongwu Lee1, Monika Hampl, Paul Albert, Howard A Fine.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a variety of transformed cell lines, but generally spares most normal cells. Transduction by an adenoviral vector expressing human TRAIL cDNA (Ad.TRAIL-GFP) resulted in both direct tumor cell killing as well as a potent bystander effect through presentation of TRAIL by transduced normal cells. Administration of Ad.TRAIL-GFP significantly prolonged survival of mice harboring either intracerebral glioblastomas or breast carcinoma-induced peritoneal carcinomatosis. Additionally, TRAIL induced prolonged transgene expression in normal tissue, presumably as a result of diminished immune-mediated destruction of vector-transduced cells. Taken together, these data suggest that vector-mediated transduction of TRAIL may represent an effective strategy for cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082547      PMCID: PMC1531709          DOI: 10.1038/sj.neo.7900245

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  32 in total

Review 1.  Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily.

Authors:  H J Gruss
Journal:  Int J Clin Lab Res       Date:  1996

2.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

3.  Identification and characterization of a new member of the TNF family that induces apoptosis.

Authors:  S R Wiley; K Schooley; P J Smolak; W S Din; C P Huang; J K Nicholl; G R Sutherland; T D Smith; C Rauch; C A Smith
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

4.  A role for CD95 ligand in preventing graft rejection.

Authors:  D Bellgrau; D Gold; H Selawry; J Moore; A Franzusoff; R C Duke
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

5.  Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo.

Authors:  Y Yang; J M Wilson
Journal:  J Immunol       Date:  1995-09-01       Impact factor: 5.422

6.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

Authors:  G Pan; J Ni; Y F Wei; G Yu; R Gentz; V M Dixit
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

7.  A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.

Authors:  M Giovarelli; P Musiani; G Garotta; R Ebner; E Di Carlo; Y Kim; P Cappello; L Rigamonti; P Bernabei; F Novelli; A Modesti; A Coletti; A K Ferrie; P L Lollini; S Ruben; T Salcedo; G Forni
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

8.  In vitro expansion of a multipotent population of human neural progenitor cells.

Authors:  M K Carpenter; X Cui; Z Y Hu; J Jackson; S Sherman; A Seiger; L U Wahlberg
Journal:  Exp Neurol       Date:  1999-08       Impact factor: 5.330

9.  Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Authors:  R M Pitti; S A Marsters; S Ruppert; C J Donahue; A Moore; A Ashkenazi
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

10.  Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.

Authors:  T Tanaka; Y Manome; P Wen; D W Kufe; H A Fine
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

View more
  13 in total

1.  The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.

Authors:  Brett D Shepard; Andrew D Badley
Journal:  Antiinfect Agents Med Chem       Date:  2009-04-01

2.  Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas.

Authors:  S A Choi; Y E Lee; P A Kwak; J Y Lee; S S Kim; S J Lee; J H Phi; K-C Wang; J Song; S H Song; K M Joo; S-K Kim
Journal:  Cancer Gene Ther       Date:  2015-05-29       Impact factor: 5.987

3.  Magnetic iron oxide nanoparticles mediated gene therapy for breast cancer--an in vitro study.

Authors:  Weizhong Wei; Chunfang Xu; Hua Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

4.  Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma.

Authors:  Seung Ah Choi; Sung-Kyun Hwang; Kyu-Chang Wang; Byung-Kyu Cho; Ji Hoon Phi; Ji Yeoun Lee; Hee Won Jung; Do-Hun Lee; Seung-Ki Kim
Journal:  Neuro Oncol       Date:  2010-11-09       Impact factor: 12.300

Review 5.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

Review 6.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

Review 7.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

8.  MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth.

Authors:  Yongli Bo; Guocai Guo; Weicheng Yao
Journal:  J Neurooncol       Date:  2013-01-22       Impact factor: 4.130

Review 9.  Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside.

Authors:  Isabelle M Germano; Emanuela Binello
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

10.  Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury.

Authors:  Lixin Sun; Jeongwu Lee; Howard A Fine
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.